The Hong Kong Society of Rheumatology Biologics Registry: Updated Report (Nov 2018)

Open access

1 Demographic Data

Up to November 2018, a total of 4848 courses of biologics were used in 2935 patients (1692 women and 1243 men) with various rheumatic diseases, according to our Registry. The mean age at commencement of treatment was 47 (range 1-89). More than half of the patients suffered from rheumatoid arthritis while the others were mainly patients with ankylosing spondylitis and psoriatic arthritis. Other indications of the biologics are shown in Table 1. The longest duration of therapy was 174 months.

Table 1

Indications of the biological agents

No. of courses (%)
Rheumatoid arthritis2553 (52.7)
Ankylosing spondylitis / Spondyloarthropathy1424 (29.4)
Psoriatic arthritis604 (12.5)
Juvenile idiopathic arthritis40 (0.8)
Adult-onset Still’s disease15 (0.3)
Behcet’s disease13 (0.3)
Crohn’s disease22 (0.5)
IgG4 Disease2 (0.04)
Inflammatory myopathies12 (0.3)
Monoarthritis1 (0.02)
Myositis Ossificans1 (0.02)
Polychondritis2 (0.04)
Sarcoidosis1 (0.02)
Sjogren’s syndrome1 (0.02)
Systemic lupus erythematosus36 (0.7)
Systemic vasculitides7 (0.1)
Uveitis2 (0.04)
MCTD/ Overlap Syndrome112 (2.3)
Total4848 (100)

2 Co-morbid Conditions

The most common co-existing medical conditions of patients using biological agents were hypertension (19%), diabetes mellitus (7.1%), fatty liver (4.7%), depression (4.7%), peptic ulcer (4.4%), previous pulmonary tuberculosis (4.1%) and chronic hepatitis B infection (3.8%). Other co-morbid conditions reported were asthma (2.5%), ischemic heart disease (2.4%), liver disease (2.3%), renal disease (2.3%), cancer (2%), hyperthyroidism (1.8%), stroke (1%), heart attack (0.7%), congestive heart failure (0.6%), epilepsy (0.6%), previous extra-pulmonary tuberculosis (0.4%), COAD (0.4%), chronic hepatitis C infection (0.3%) and demyelination (0.03%).

3 Discontinuation of Treatment

The usage of biological agents is updated in Table 2 & Figures 1, 2, 3. About one-fourth of the treatment courses involved Etanercept, which remained the commonest biological agent ever used. Etanercept was also the most frequent agent that was currently used by patients (24.7%).

Table 2

Biological / targeted DMARDs used

No. of courses (%)No. of patients (%)
(ever use)(current use: up to Nov 2018)
Etanercept1246 (25.7)520 (24.7)
Adalimumab814 (16.8)403 (19.1)
Infliximab766 (15.8)93 (4.4)
Golimumab686 (14.2)363 (17.2)
Tocilizumab542 (11.2)303 (14.4)
Rituximab208 (4.3)91 (4.3)
Abatacept206 (4.3)77 (3.7)
Certolizumab143 (3.0)96 (4.6)
Tofacitinib121 (3.0)82 (3.9)
Secukinumab71 (1.5)63 (3.0)
Belimumab17 (0.4)8 (0.4)
Ustekinumab16 (0.3)6 (0.3)
Pamidronate11 (0.2)0 (0.0)
Remsima1 (0.02)1 (0.05)
(biosimilar of Infliximab)
Total4848 (100)2106 (100)
Figure 1
Figure 1

Use of b/tsDMARDs in rheumatoid arthritis (up to Nov 2018)

Citation: Hong Kong Bulletin on Rheumatic Diseases 18, 2; 10.2478/hkbrd-2018-0010

Figure 2
Figure 2

Use of bDMARDs in spondyloarthritis (up to Nov 2018)

Citation: Hong Kong Bulletin on Rheumatic Diseases 18, 2; 10.2478/hkbrd-2018-0010

Figure 3
Figure 3

Use of bDMARDs in Psoriatic arthritis (up to Nov 2018)

Citation: Hong Kong Bulletin on Rheumatic Diseases 18, 2; 10.2478/hkbrd-2018-0010

The number of patients who withdrew from treatment at different time points is shown in Table 3. The three most commonly reported reasons for termination of treatment are lack of efficacy (46%), serious adverse effects (21%) and cost (11%). Other reasons for stopping treatment included marked improvement of disease activity (8%), end of research study (7%), patients’ preference (3%) etc.

Table 3

Withdrawal of biological therapies

Follow up duration reported to registry since commencement of biological therapy (months)
036121824303642485460667278849096102108114120126132138144150156162168174
No. of courses registered in FU48484416370429052169178214691230101185369357145636027521416713091766245352924171410853
No. of courses continue4848386831482339189916071336114192679064052541733125220115311688705843332821151210852
No. of withdrawal054855656627017513389856353463929231314143642213220001
Reasons for withdrawal
Lack of efficacy0187297286124686034413526192014156472421101110001
Cost0685561372215785561320020000000000000
Adverse effects0217857748372416101013118525830100100110000
End of sample0297250691000056010000000000000000
Plan for surgery / pregnancy02112821421021100100000010000000
Defaulted FU041111715302000000010000000000000
Remission020224828232022187433421101101002000000
Others01610189124362500210010010000000000
Dead0333213001000001000000000000000
Unknown0200100000000000000010000000000

4 Major Adverse Events Reported

4.1 Neoplasia

There were 51 cases of malignant and pre-malignant conditions reported: lung cancer (N=5), rectum cancer (N=5), colon cancer (N=4), breast cancer (N=4), ovarian cancer (N=4), lymphoma (N=2), nasopharyngeal cancer (N=2), pulmonary MALT lymphoma (N=1), tongue cancer (N=1), caecum cancer (N=1), intraductal papillary mucinous neoplasm of pancreas (N=1), prostate cancer (N=1), stomach cancer (N=1), penile cancer (N=1), gall bladder cancer (N=1), cancer of urinary bladder (N=1), cancer of small intestine (N=1), kidney cancer (N=1), cancer of ampulla of vater (N=1), thyroid cancer (N=1), mandible cancer (N=1), adenocarcinoma (N=1), myeloma (N=1), cervical intra-epithelial neoplasia (CIN) (N=1), myelodysplastic syndrome (N=1), brain tumor (N=1), malignant melanoma (N=1), renal cell carcinoma (N=1), cervical cancer (N=1), cancer of nasal cavity (N=1), laryngeal cancer (N=1) and myeloproliferative neoplasms (N=1).

4.2 Infection Requiring Hospitalization

There were 172 episodes of infective complications requiring hospitalization. Over 55% of them (i.e. 95 cases) occurred during the first 12 months of biological therapy.

4.3 Tuberculosis

A total of 67 cases of TB were reported: 32 related to Infliximab, 12 related to Etanercept, 12 related to Adalimumab, 6 related to Golimumab, 3 related to Tocilizumab and 2 related to Tofacitinib. Half of the cases (i.e. 34 cases) occurred in the first year of treatment. Isoniazid chemoprophylaxis was given to 997 patients (22.3% of all courses of b/tsDMARDs) with latent TB as defined by either positive MT2 (≥10mm induration) or a positive IGRA test.

If the inline PDF is not rendering correctly, you can download the PDF file here.

Search
Journal information
Figures
Metrics
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 95 95 17
PDF Downloads 24 24 1